Compounds > pramipexole
Page last updated: 2024-09-03

pramipexole and n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide

pramipexole has been researched along with n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide in 1 studies

Compound Research Comparison

Studies
(pramipexole)		Trials
(pramipexole)		Recent Studies (post-2010)
(pramipexole)		Studies
(n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide)		Trials
(n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide)		Recent Studies (post-2010) (n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide)
1,10321951716518109

Protein Interaction Comparison

ProteinTaxonomypramipexole (IC50)n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide (IC50)
D(2) dopamine receptorHomo sapiens (human)0.005

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Albert, NL; Bartenstein, P; Boetzel, K; Cumming, P; Deutschländer, A; Gildehaus, FJ; la Fougère, C; Xiong, G1

Other Studies

1 other study(ies) available for pramipexole and n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide

ArticleYear
Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.
    NeuroImage. Clinical, 2016, Volume: 12

    Topics: Aged; Benzamides; Benzothiazoles; Dopamine Agonists; Dopamine Antagonists; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Pramipexole; Radiopharmaceuticals; Receptors, Dopamine D2; Receptors, Dopamine D3

2016